Showing 1941-1950 of 2314 results for "".
- Haag-Streit Introduces the Imaging Module 910 Slit Lamphttps://modernod.com/news/haag-streit-launhces-the-imaging-module-910-slit-lamp/2480718/Haag-Streit announced the launch of the Imaging Module 910 slit lamp. The device is instantly ready by the turn of a knob and does not require using software. Haag-Streit says capturing images is equally easy—pressing the camera trigger button is all that it takes. "
- LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-us-lightsite-iii-clinical-trial-meets-primary-efficacy-endpoint-in-improving-vision-in-dry-amd-patients/2480712/LumiThera announced positive findings in its LIGHTSITE III multicenter clinical trial in non-neovascular (dry) age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked, randomized, multicenter clinica
- Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successorhttps://modernod.com/news/spark-therapeutics-announces-departure-of-ceo-and-founder-jeff-marrazzo-coo-ron-philip-named-as-successor/2480664/Spark Therapeutics, a member of the Roche Group, announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer. Mr. Marrazzo, who co-founded the company in 2013, will step down on April 1. “When I thin
- Nicox Announces Vyzulta Now Commercialized in 7 Territories and Approved in Further 9 Countrieshttps://modernod.com/news/nicox-announces-vyzulta-now-commercialized-in-7-territories-and-approved-in-further-9-countries/2480660/Nicox provided an update on the approvals and launches of Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%, exclusively licensed worldwide by Nicox to Bausch + Lomb. “Vyzulta is the first product based on our nitric oxide-donating research platform which has bee
- Phase 4 Study of Iluvien for DME Shows Statistically Significant Improvements in BCVA, CST, and Treatment Burden at 36 Monthshttps://modernod.com/news/phase-4-paladin-study-with-iluvien-published-in-peer-reviewed-journal-ophthalmology/2480659/Alimera Sciences announced that the 3-year results of the PALADIN study have been published in the peer-reviewed journal Ophthalmology. These study results show that patients with diabetic macular edema (DME) who received a single dose of the sustained release implant Iluv
- EyeQue Launches MyReaderNumber App: Personalized Results for Reading and Computer Glasseshttps://modernod.com/news/eyeque-launches-myreadernumber-app-personalized-results-for-reading-and-computer-glasses-1/2480648/EyeQue introduced a first-of-its-kind smartphone app called MyReaderNumber that offers AR technology vision testing for presbyopia. EyeQue’s MyReaderNumber app is available for download for a one-time fee of $2.99 on the App Store (iOS only; available for iPhone X and newer) and c
- Novartis Presents Positive Results From Three Phase 3 Trials of Beovu in DMEhttps://modernod.com/news/novartis-presented-positive-results-from-three-phase-3-trials-of-beovu-in-dme/2480638/At the Angiogenesis, Exudation, and Degeneration 2022 Virtual Meeting, Novartis presented additional positive results from three phase 3 trials of Beovu in DME, including results from patients dosed at up to 16-week intervals. This was the first detailed presentation of the year 2 results&nb
- Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Modelhttps://modernod.com/news/aldeyra-therapeutics-announces-publication-of-phase-2-clinical-trial-of-reproxalap-in-allergen-chamber-model/2480608/Aldeyra Therapeutics announced that results from the randomized, double-masked, vehicle-controlled, crossover phase 2 clinical trial of reproxalap in an allergen chamber model have been published in the peer-reviewed journal Clinical Ophthalmology.1 Reproxalap, an
- AI Can Identify Heart Disease From an Eye Scanhttps://modernod.com/news/ai-can-identify-heart-disease-from-an-eye-scan/2480602/Scientists have developed an artificial intelligence system that can analyze eye scans taken during a routine visit to an optician or eye clinic and identify patients at a high risk of a heart attack, according to a University of Leeds, UK, news release. Doctors have recognized th
- Rayner Appoints Ophthalmic Leaders as Strategic Advisors and is Awarded IDE for Trifocal IOLshttps://modernod.com/news/rayner-appoints-esteemed-ophthalmic-leaders-as-strategic-advisors-and-is-awarded-ide-for-trifocal-iols/2480533/Rayner has announced the appointment of Eric Donnenfeld, MD; Kerry Solomon, MD; Vance Thompson, MD; and Jim Mazzo as strategic advisors to the business, with a